National Trends in Use of and Spending on Oral Anticoagulants Among US Medicare Beneficiaries From 2011 to 2019
Authors:
Open Access
- 23 July 2021
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 2 (7) , e211693
Abstract
Direct oral anticoagulants (DOACs) reached the market in 2010 and are associated with lower bleeding risks and decreased monitoring compared with warfarin, but also higher costs.1 Early adoption of DOACs was brisk, but to our knowledge, little is known about recent patterns of oral anticoagulant use and how the introduction of competing DOACs have affected Medicare spending.2Keywords
This publication has 5 references indexed in Scilit:
- Estimating Rebates and Other Discounts Received by Medicare Part DJAMA Health Forum, 2021
- Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020JAMA Network Open, 2021
- Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline UpdatesCirculation, 2019
- Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation PatientsStroke, 2016
- Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation— Quality and Cost ImplicationsThe American Journal of Medicine, 2014